340BDrug PricesDrug PricingFeaturedHealth careObamaCare

It’s Time For Congress To Get 340B Out Of Its Blind Spot

If a charity organization collected billions of dollars with little evidence that needy people benefited, regulators and the public would quickly demand answers.

Yet many large hospital systems participating in the federal 340B Drug Pricing Program are quietly doing just that—extracting billions in drug discounts with scarce oversight and no obligation to prove vulnerable patients benefit.

Source link

Related Posts

1 of 223